MGP
CRNX icon

M&G plc’s Crinetics Pharmaceuticals CRNX Stock Holding History

M&G plc’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-281,896
Closed -$8.17M – 389
2025
Q2 		$8.17M Buy
281,896
+74
+0% +$2.29K 0.05% 238
2025
Q1 		$9.58M Buy
+281,822
New +$10.5M 0.05% 207

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

M&G plc's CRNX Position: Q3 2025 in Review

M&G plc sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2025, closing a stake of 281,896 shares — an estimated $8.17M sold.

M&G plc first reported a position in CRNX in Q1 2025 and held it in 2 quarters. The position peaked at $9.58M in Q1 2025. 225 funds tracked by Wall St. Rank hold CRNX as of Q3 2025.

  • M&G plc reported no remaining Crinetics Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • M&G plc sold 281,896 Crinetics Pharmaceuticals shares in Q3 2025, an estimated $8.17M.
  • M&G plc first reported a position in Crinetics Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • M&G plc's Crinetics Pharmaceuticals position peaked at $9.58M in Q1 2025.
  • 225 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2025.

Based on M&G plc's 13F filing for Q3 2025, filed 7 Nov 2025.